Mobile Health Device Study for Myeloma Patients

Inclusion Criteria

Newly diagnosed Multiple Myeloma meeting International Myeloma Working Group (IMWG) criteria (as below) participants with clinical and histological confirmation of diagnosis planning to receive chemotherapy are eligible:

Newly diagnosed Multiple Myeloma patients will have evidence of underlying end organ damage and/or myeloma defining event attributed to underlying plasma cell proliferative disorder meeting at least one of the following:
Hypercalcemia: serum calcium >0.25 mmol/L (> 1 mg/dL) above upper limit of normal or ≥ 2.75 mmol/L (11 mg/dL)
Anemia: hemoglobin value <10 g/dL or > 2 g/dL below lower limit of normal
Bone disease: ≥ 1 lytic lesions on skeletal X-ray, CT, or PET-CT. For patients with 1 lytic lesion, bone marrow should demonstrate ≥ 10% clonal plasma cells
Clonal bone marrow plasma cell percentage ≥ 60%
Involved/un-involved serum free light chain ratio ≥100 and involved free light chain >100 mg/L
> 1 focal lesion on magnetic resonance imaging study (lesion must be >5 mm) in size
All study participants will be required to receive primary chemotherapy treatment at a Memorial Sloan Kettering facility, including regional outpatient sites.
All study participants will be required to have a smart phone or tablet device compatible with the Garmin Vivofit device.

Exclusion Criteria

Plasma cell leukemia
POEMS syndrome
Amyloidosis